28-day mortality in high-risk with severe sepsis receiving eritoran with or without drotrecogin alfa: Analysis of data from a phase II trial
Author Department
Medicine
Document Type
Presentations, Research
Publication Date
1-1-2010
Recommended Citation
Kinasewitz g, Tidswell M. 28-day mortality in high-risk with severe sepsis receiving eritoran with or without drotrecogin alfa: Analysis of data from a phase II trial. Society of Critical Care Medicine Critical Care Congress. San Diego, CA. 2010.
COinS